Nanoparticle delivery of an akt/pdk1 inhibitor improves the therapeutic effect in pancreatic cancer

Armando Lucero-Acuña, Justin J. Jeffery, Edward R. Abril, Raymond B Nagle, Roberto Z Guzman, Mark "Marty" Pagel, Emmanuelle Meuillet

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a poor therapeutic effect against a MiaPaCa-2 pancreatic cancer model with mutant K-ras. To increase the therapeutic effect of PH-427 against the MiaPaCa-2 pancreatic cancer model with mutant K-ras, we encapsulated PH-427 into poly(lactic-co-glycolic acid) nanoparticles (PNP) to form drug-loaded PH-427-PNP. PH-427 showed a biphasic release from PH-427-PNP over 30 days during studies in sodium phosphate buffer, and in vitro stud­ies revealed that the PNP was rapidly internalized into MiaPaCa-2 tumor cells, suggesting that PNP can improve PH-427 delivery into cells harboring mutant K-ras. In vivo studies of an orthotopic MiaPaCa-2 pancreatic cancer model showed reduced tumor load with PH-427-PNP as compared with treatment using PH-427 alone or with no treatment. Ex vivo studies confirmed the in vivo results, suggesting that PNP can improve drug delivery to pancreatic cancer harbor­ing mutant K-ras.

Original languageEnglish (US)
Pages (from-to)5653-5665
Number of pages13
JournalInternational Journal of Nanomedicine
Volume9
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Therapeutic Uses
Pancreatic Neoplasms
Nanoparticles
Drug delivery
Tumors
Pharmaceutical Preparations
Buffers
Phosphates
Cells
Sodium
Tumor Burden
Drug Resistance
Molecules
Acids
Mutation
Neoplasms

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Organic Chemistry
  • Drug Discovery

Cite this

Nanoparticle delivery of an akt/pdk1 inhibitor improves the therapeutic effect in pancreatic cancer. / Lucero-Acuña, Armando; Jeffery, Justin J.; Abril, Edward R.; Nagle, Raymond B; Guzman, Roberto Z; Pagel, Mark "Marty"; Meuillet, Emmanuelle.

In: International Journal of Nanomedicine, Vol. 9, No. 1, 2014, p. 5653-5665.

Research output: Contribution to journalArticle

@article{d263e1d43b0d4a9f929969759f94435f,
title = "Nanoparticle delivery of an akt/pdk1 inhibitor improves the therapeutic effect in pancreatic cancer",
abstract = "The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a poor therapeutic effect against a MiaPaCa-2 pancreatic cancer model with mutant K-ras. To increase the therapeutic effect of PH-427 against the MiaPaCa-2 pancreatic cancer model with mutant K-ras, we encapsulated PH-427 into poly(lactic-co-glycolic acid) nanoparticles (PNP) to form drug-loaded PH-427-PNP. PH-427 showed a biphasic release from PH-427-PNP over 30 days during studies in sodium phosphate buffer, and in vitro stud­ies revealed that the PNP was rapidly internalized into MiaPaCa-2 tumor cells, suggesting that PNP can improve PH-427 delivery into cells harboring mutant K-ras. In vivo studies of an orthotopic MiaPaCa-2 pancreatic cancer model showed reduced tumor load with PH-427-PNP as compared with treatment using PH-427 alone or with no treatment. Ex vivo studies confirmed the in vivo results, suggesting that PNP can improve drug delivery to pancreatic cancer harbor­ing mutant K-ras.",
author = "Armando Lucero-Acu{\~n}a and Jeffery, {Justin J.} and Abril, {Edward R.} and Nagle, {Raymond B} and Guzman, {Roberto Z} and Pagel, {Mark {"}Marty{"}} and Emmanuelle Meuillet",
year = "2014",
doi = "10.2147/IJN.S68511",
language = "English (US)",
volume = "9",
pages = "5653--5665",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Nanoparticle delivery of an akt/pdk1 inhibitor improves the therapeutic effect in pancreatic cancer

AU - Lucero-Acuña, Armando

AU - Jeffery, Justin J.

AU - Abril, Edward R.

AU - Nagle, Raymond B

AU - Guzman, Roberto Z

AU - Pagel, Mark "Marty"

AU - Meuillet, Emmanuelle

PY - 2014

Y1 - 2014

N2 - The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a poor therapeutic effect against a MiaPaCa-2 pancreatic cancer model with mutant K-ras. To increase the therapeutic effect of PH-427 against the MiaPaCa-2 pancreatic cancer model with mutant K-ras, we encapsulated PH-427 into poly(lactic-co-glycolic acid) nanoparticles (PNP) to form drug-loaded PH-427-PNP. PH-427 showed a biphasic release from PH-427-PNP over 30 days during studies in sodium phosphate buffer, and in vitro stud­ies revealed that the PNP was rapidly internalized into MiaPaCa-2 tumor cells, suggesting that PNP can improve PH-427 delivery into cells harboring mutant K-ras. In vivo studies of an orthotopic MiaPaCa-2 pancreatic cancer model showed reduced tumor load with PH-427-PNP as compared with treatment using PH-427 alone or with no treatment. Ex vivo studies confirmed the in vivo results, suggesting that PNP can improve drug delivery to pancreatic cancer harbor­ing mutant K-ras.

AB - The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a poor therapeutic effect against a MiaPaCa-2 pancreatic cancer model with mutant K-ras. To increase the therapeutic effect of PH-427 against the MiaPaCa-2 pancreatic cancer model with mutant K-ras, we encapsulated PH-427 into poly(lactic-co-glycolic acid) nanoparticles (PNP) to form drug-loaded PH-427-PNP. PH-427 showed a biphasic release from PH-427-PNP over 30 days during studies in sodium phosphate buffer, and in vitro stud­ies revealed that the PNP was rapidly internalized into MiaPaCa-2 tumor cells, suggesting that PNP can improve PH-427 delivery into cells harboring mutant K-ras. In vivo studies of an orthotopic MiaPaCa-2 pancreatic cancer model showed reduced tumor load with PH-427-PNP as compared with treatment using PH-427 alone or with no treatment. Ex vivo studies confirmed the in vivo results, suggesting that PNP can improve drug delivery to pancreatic cancer harbor­ing mutant K-ras.

UR - http://www.scopus.com/inward/record.url?scp=84914675536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914675536&partnerID=8YFLogxK

U2 - 10.2147/IJN.S68511

DO - 10.2147/IJN.S68511

M3 - Article

C2 - 25516710

AN - SCOPUS:84914675536

VL - 9

SP - 5653

EP - 5665

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

IS - 1

ER -